Healthcare entity

BPL-003

Product

All 1 tracked stories fall under one category: market-trends. BPL-003 is most often covered alongside AtaiBeckley, which appears in 1 of these 1 story. BPL-003 appears in 1 tracked Healthcare story from March 8, 2026. The tracked stories average 2 original sources each.

Last mentioned: Aug 5, 2026

RSS updates
Share

Entity pulse

Recent coverage · BPL-003

1 story
6 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about BPL-003

All 1 tracked stories fall under one category: market-trends. BPL-003 is most often covered alongside AtaiBeckley, which appears in 1 of these 1 story. BPL-003 appears in 1 tracked Healthcare story from March 8, 2026. The tracked stories average 2 original sources each.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 15 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering BPL-003. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Phase 3 Initiation

    Expected launch of the global Phase 3 program for BPL-003 in TRD.

  2. Results Announcement

    Company reports 2025 results and confirms Phase 3 timeline.

  3. Fiscal Year End

    AtaiBeckley completes 2025 with focused R&D spending on lead assets.

  4. Strategic Investment

    atai Life Sciences invests $50M in Beckley Psytech to accelerate BPL-003.

Stories mentioning BPL-003 1

BPL-003 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.